https://scholars.lib.ntu.edu.tw/handle/123456789/588818
標題: | Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor | 作者: | KUAN-YIN LIN Cheng C.-Y. Yang C.-J. Tsai M.-S. SZU-MIN HSIEH HSIN-YUN SUN WANG-HUEI SHENG Chen M.-Y. SUI-YUAN CHANG Cheng S.-H. CHIEN-CHING HUNG |
公開日期: | 2014 | 卷: | 20 | 期: | 8 | 起(迄)頁: | 465-470 | 來源出版物: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy | 摘要: | RESULTS: During the study period, 238 patients who switched to once-daily DRV/RTV-containing regimens (Group A) and 178 patients who switched from 2 NRTIs plus nNRTI or other PI to 2 NRTIs plus PI other than DRV/RTV (Group B) were included. There were no differences between Groups A and B in most of the baseline characteristics. Compared with Group B in which 7 (3.9%) developed rashes after switch to PI other than DRV, 26 patients (10.9%) in Group A developed rashes after a median interval of 14 days of starting DRV/RTV-containing regimens (P = 0.009). In multivariate analysis, patients with a history of rashes related to the previous nNRTI-containing regimens before starting DRV/RTV-containing regimens were more likely to develop rashes with an adjusted odds ratio of 3.53 (95% confidence interval, 1.45-8.62).CONCLUSIONS: Once-daily regimens containing DRV/RTV is associated with a higher rate of adverse cutaneous reactions than other PI-containing regimens in HIV-infected Taiwanese, especially in those who have a history of rashes to nNRTI-containing regimens before switch to DRV/RTV-containing regimens.OBJECTIVES: The study aimed to investigate the incidence of and associated factors with skin rashes among HIV-infected Taiwanese patients who received once-daily darunavir (DRV) boosted by ritonavir (RTV) (800/100 mg) plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs).METHODS: We reviewed the medical records of HIV-infected patients who switched to once-daily DRV/RTV-containing regimens between January 2012 and November 2013. Patients who switched from 2 NRTIs plus non-NRTI (nNRTI) or other protease inhibitor (PI) to 2 NRTIs plus PIs other than DRV were chosen as comparators. Copyright ? 2014. Published by Elsevier Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925883578&doi=10.1016%2fj.jiac.2014.04.006&partnerID=40&md5=5c284d26ee9d894fd69128bddbed7afa https://scholars.lib.ntu.edu.tw/handle/123456789/588818 |
ISSN: | 1437-7780 | DOI: | 10.1016/j.jiac.2014.04.006 | SDG/關鍵字: | antiretrovirus agent; darunavir; sulfonamide; adult; complication; Exanthema; female; HIV Infections; human; incidence; male; middle aged; retrospective study; risk factor; Taiwan; Adult; Anti-Retroviral Agents; Exanthema; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Risk Factors; Sulfonamides; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。